Group items matching

in title, tags, annotations or url

Diabetes affects over 537 million people worldwide; by 2045, this is estimated to increase to 783 million. [1] With the growing prevalence of diabetes, it's even more important to utilise all options to support people with diabetes (PwDs) in managing their daily life with diabetes. Where do PwDs most often access healthcare support? On average, PwDs visit the pharmacy three-to-eight times more than the general population to obtain medicines and testing supplies.[2] It is clear that pharmacists play an integral role in empowering the self-management needs of PwDs beyond the traditional role of supplying medicines. This relationship, however, may be underutilised. Research suggests there is a lack of broad recognition of pharmacists as a key source of diabetes care, and that resource constraints - particularly following the COVID-19 pandemic - can interfere with patient education provision and training.[3,4] Furthermore, the circumstances and role of the pharmacy vary, nationally and internationally. At Roche Diabetes Care we would like to shine a light on the increasing value of community pharmacists as important figures in the well-being of PwDs.

The US Food and Drug Administration (FDA) has approved the Novartis drug, Cosentyx, (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. HS is a chronic, progressive and painful disease which affects one in 100 people worldwide, and has limited treatment options. "Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS," said the Swiss company. The FDA approval was based on robust Phase III data (SUNSHINE and SUNRISE studies) in which Cosentyx showed rapid relief from HS symptoms as early as Week 21.

The Royal Pharmaceutical Society (RPS) has awarded Professor Abdul Basit with the RPS Harrison Memorial Medal for an outstanding contribution to advancing pharmaceutical science. Professor Basit graduated with a First Class Honours degree in Pharmacy from the University of Bath, and received his PhD from The School of Pharmacy, University of London. Currently in position as Professor of Pharmaceutics at the UCL School of Pharmacy, he is internationally recognised for leading in the field of drug delivery, microbiome medicines, three-dimensional printing of pharmaceuticals and digital health. He has also founded three start-up companies. Professor Basit has an impressive track record of publications, and a lifetime grant and investment income of over £100million pounds. His research has led to a series of transformative drug delivery systems, translated into the design of new technologies and improved therapies, many of which have been commercialised and launched worldwide including a new treatment for inflammatory bowel disease. To date, more than a million patients have benefited from inventions created and developed in the Basit Research Group.

Covid-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they could over the last 18 months. Executives at the biggest Covid vaccine makers including Pfizer and Moderna said they believe most people who wanted to get vaccinated against Covid have already done so - more than five billion people worldwide. In the coming year, most Covid vaccinations will be booster shots, or first inoculations for children, which are still gaining regulatory approvals around the world, they said. Pfizer, which makes its shot with Germany's BioNTech and Moderna still see a major role for themselves in the vaccine market even as overall demand declines. Upstart US vaccine maker Novavax and Germany's CureVac, which is working with GlaxoSmithKline, are developing vaccines they hope to target at the booster market. The roles of AstraZeneca and Johnson & Johnson, whose shots have been less popular or effective, are expected to decline in this market.

The Medicines and Healthcare products Regulatory Agency (MHRA) has been accepted as a full member of three international work-sharing partnerships. Through these partnerships the agency said it will play vital international role in making sure medicines and medical devices are regulated safely and efficiently worldwide, Two of these, the International Medical Device Regulatory Forum (IMDRF) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) are focused on improving the harmonisation and convergence of medicines and medical devices regulation globally. The partnerships will also help the MHRA to share expertise with other leading organisations, support the development of regulatory guidelines and drive greater harmonisation of regulation around the world. This will help deliver timely access to innovative medical products not just in the UK but globally.

Polio has been detected in sewage samples in London, the first sign since the 1980s that the virus could be spreading in the UK, but no cases have been found, authorities said. The risk of infection from the disease, which causes paralysis in children in under one per cent of cases, was also low because of high vaccination rates, the UK Health Security Agency (UKHSA) said. The agency nevertheless encouraged parents to make sure their children were vaccinated after the discovery of the virus during routine wastewater surveillance - particularly those who may have missed shots during the Covid-19 pandemic. Nationwide vaccination levels are above the 90 per cent needed to prevent outbreaks, but London's coverage rates among the under-twos has dipped below that in recent years. NHS England will begin contacting parents of children under five who are not immunised. Polio, spread mainly through contamination by faecal matter, used to kill and paralyse thousands of children annually worldwide. There is no cure, but vaccination brought the world close to ending the wild, or naturally occurring, form of the disease.

According to Alzheimer's Disease International, more than 55 million people worldwide will have Alzheimer's disease by 2020. This figure will nearly double every 20 years, reaching 78 million in 2030 and 139 million in 2050. The WHO Global Status Report for 2021 estimated the yearly global cost of dementia to be more than USD 1.3 trillion, with a projected increase to USD 2.8 trillion by 2030. To date most drugs developed to treat Alzheimer's disease have failed, largely because they target wrong biomarkers and individuals already exhibiting signs of the disease. Once symptoms appear, however, many brain cells responsible for memory and cognition are likely already damaged and beyond repair. Professor Shai Rahimipour in the Chemistry Department at Bar-Ilan University in Israel has pioneered a different approach utilizing theranostics to pinpoint and treat the earliest, pre-symptomatic signs of Alzheimer's disease. Showing promise in stopping progression of the disease before onset of irreversible brain cell damage, Rahimipour's groundbreaking approach has garnered significant attention in the scientific world.

Many advertised the elderberry due to its immune-boosting effects during the pandemic. Elderberry has been sold to benefit colds and flu. Some exponents even asserted they benefit against COVID-19. You also may have heard that they can help with other ailments, like diabetes, high blood pressure, and high cholesterol. Still, no one-size-fits-all remedy for sickness like turmeric exists. Exponents of the elderberry say it is a versatile fruit of nature and is a solution to what ails you. About 30 types of elderberry plants exist worldwide. In the European version, it is Sambucus nigra, which means closely affixed to your health and healing. It dates back to 400 BC. Hippocrates (Father of Medicine) called the elderberry his "medicine chest." Now elderberry is viewed as one of the world's most healing plants in folk medicine. So what's the deal? Is the elderberry plant a godsend fruit that can give you super immunity? What are Elderberries? You're probably familiar with elderberries, which look like any other dark blueberry. But there are many plant species, and they all have unique characteristics that might surprise you. Sambucus contains over 30 species of shrubs in the Adoxaceae family, including honeysuckle and snowberry (Symphoricarpos). The elderberry grows throughout Europe, Asia, and North America-and even as far north as Alaska! It thrives in moist areas such as river banks, fields, and forest margins, where it can grow up to 8 feet tall (2.4 meters). Elderberry flowers from May through July, depending on region; clusters of white flowers grow on cymes at the ends of branches before turning into red berries by late summer or early fall. Historical and Regional Uses People have used Elderberries for decades since the fifth century AD. Still, if you see the plant's name, you'll notice that the Elder shrub was so revered that its very name shows the respect it was given. Being grown by Native American and European herbalists throughout history,

Chiesi Farmaceutici, the international, research-focused biopharmaceuticals and healthcare group has acquired Amryt Pharma, a global biopharmaceutical company dedicated to developing novel treatments for rare diseases. More than 300 million people worldwide are affected by rare diseases, including those who are living with ultra-rare metabolic and dermatologic conditions who still have no approved treatment. The acquisition reinforces Chiesi's commitment to deliver innovative treatments to patients with highly unmet medical needs. As a benefit corporation and a B Corp, Chiesi strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. Chiesi's Head of Chiesi Global Rare diseases Giacomo Chiesi commented: "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to rare diseases and aligns with our growth strategy through partnerships beyond internal research and development." Chiesi's new CEO Giuseppe Accogli said: "By joining forces and expertise we will be able to grow our capabilities and further strengthen our position to provide a positive impact on patients living with rare diseases." With regard to the financing of the deal, cash consideration has been partially financed through a EUR 700m syndicated loan led by BNP Paribas and Crédit Agricole as Global Coordinators and ESG Structuring Banks, acting alongside BPER and Deutsche Bank as Mandated Lead Arrangers. Crédit Agricole is Loan Agent too. Lenders have been advised by Clifford Chance, while Baker and McKenzie has assisted Chiesi Farmaceutici.

John Dawson, the founder and former CEO of Alliance Pharma, has donated £5million to the University of Sunderland towards the creation of a new drug research centre. The donation - the biggest in the university's history - will create the John Dawson Drug Discovery and Development Research Institute to improve health and wellbeing of millions of people worldwide. The new centre has been named after the pharmaceutical entrepreneur and Sunderland graduate who, alongside wife Sam, has provided the funding. He and Sam were on Thursday (April 20) joined by specially invited guests from across the region's health, education, and business communities, to launch the Institute housed in the University's Sciences Complex. Unveiling a plaque inside the building, John said: "It's an absolute honour and privilege to be able to launch the new Drug Discovery and Development Research Institute at the University of Sunderland today. "It's been wonderful to be back on the campus and see the incredible developments that have taken place since I studied pharmacy here more than 50 years ago. "I was immediately impressed at what has been achieved in that intervening half-century and I've been delighted to assist the University continue its development, particularly in the health arena. "I hope the launch of this institute will mark the next phase in the University's evolution and I'm very much looking forward to working with the team as they bring their projects to fruition."

The Medicines and Healthcare products Regulatory Agency (MHRA) on Wednesday (9 January) announced that the novel type 2 oral polio vaccine (nOPV2) has been quality-assured (prequalified) by the World Health Organization (WHO). Developed by a team including scientists from the MHRA, nOPV2 is considered a safer polio vaccine that helps to protect children from the disabling and life-threatening disease and lower the risk of vaccine-derived outbreaks. The vaccine received WHO Emergency Use Listing three years ago, and since then 950 million doses have been delivered worldwide. The UN health agency's decision to add it to the list of prequalified vaccines is based on the analysis of outcomes in vaccinated populations that has confirmed strong safety profile and effectiveness.

People worldwide encounter a variety of eye issues. Fortunately, modern medicine has made significant strides in surgical techniques that effectively address many eye problems, including conditions like glaucoma and cataracts.

Hey there, folks! Ever find yourself caught up in the throes of pain, wondering if there's a better way to handle it? You're not alone. In fact, according to recent stats, a whopping 93% of people worldwide grapple with pain annually. And get this: 1 in 3 folks deal with it every single day. Crazy, right? But here's the kicker: despite pain being such a prevalent issue, many folks aren't tackling it head-on. Yep, you heard that right. There's a whole lot of suffering going on, and not enough proactive pain management happening. So, what's the solution? Well, that's where our Pain Management Webinar swoops in to save the day! Picture this: an hour jam-packed with enlightening insights, carefully curated to arm you and your team with the tools needed to understand, manage, and ease pain in your patients' lives. Diving Deep: What's Inside the Webinar Alright, buckle up because we're about to dive into the juicy details of what this webinar has in store for you. 1. The Evolving Role of Pharmacists First up, we're shedding light on the evolving role of pharmacists in the realm of pain management. Yep, you heard that right. It's not just about doling out pills anymore. Pharmacists are becoming key players in the fight against pain, and we'll show you exactly how. 2. Decoding Pain Assessment Ever struggle to figure out just how much pain your patients are in? We feel you. That's why we're dedicating some time to decode the art of pain assessment. By the time you're done with this segment, you'll be a pro at understanding and quantifying your patients' pain levels. 3. #ListenToPain: A Campaign for Better Conversations And last but certainly not least, we're shining a spotlight on Haleon's #ListenToPain campaign. This bad boy is all about fostering better conversations between you and your patients. Trust us, folks, communication is key when it comes to pain management, and this campaign's got all the tools you need to nail those conversations. Tailored Jus

Join the battle against pain! Worldwide, 93% experience it annually, with 1 in 3 enduring daily agony. But our approach needs refinement. Introducing our Pain Management Webinar! In just 60 minutes, equip yourself with strategies to combat pain effectively. Here's what's covered: Pharmacists' Evolving Role: Moving beyond medication. Perfecting Pain Assessment: Quantifying patient discomfort. #ListenToPain: Enhancing patient communication. Tailored for British pharmacists addressing acute and chronic pain. Seize this opportunity to make a tangible difference. Reserve your spot now for invaluable insights!

Despite the pervasive nature of pain, affecting 93% of the global population annually and leaving one in three individuals in daily discomfort, there exists a concerning reluctance to address and manage pain effectively. This leads to a heightened burden of suffering among people worldwide. Join our complimentary 1-hour Pain Management Webinar, meticulously crafted to equip you and your team with vital strategies to comprehend, address, and alleviate pain in your patients' lives. Delve into topics such as the pharmacist's evolving role, the significance of timely pain treatment, and initiatives like Haleon's #ListenToPain campaign. This webinar is tailored for pharmacists in GB, especially those in community, practice, PCN, and hospital settings. Don't miss this chance to enhance patient care and contribute positively to pain management. Register now to reserve your spot!

Despite the widespread prevalence of pain, which affects 93% of the global population annually and leaves one in three individuals experiencing daily discomfort, there is a troubling reluctance to effectively address and manage pain. This reluctance contributes to increased suffering among people worldwide. We invite you to join our complimentary 1-hour Pain Management Webinar, thoughtfully designed to provide you and your team with essential strategies for understanding, addressing, and alleviating pain in your patients' lives. Explore topics such as the evolving role of pharmacists, the importance of timely pain treatment, and initiatives like Haleon's #ListenToPain campaign. This webinar is tailored for pharmacists in Great Britain, particularly those working in community, practice, PCN, and hospital settings. Don't miss this opportunity to improve patient care and make a positive impact on pain management. Register now to secure your spot!

We all know that pain is a universal experience. The management of pain remains a significant challenge worldwide. The ever-growing statistics reveal the importance of pain. There persists concern about inertia in both acknowledging and effectively treating it. According to the Global Pain Index, a comprehensive social study conducted with 19,000 consumers in 2020, a staggering 93% of the world's population experiences pain within a year, with 1 in 3 individuals grappling with it daily.

People worldwide encounter a variety of eye issues, but modern medicine has made significant advancements in surgical techniques to effectively address many eye problems, including conditions like glaucoma and cataracts.

The government will on Thursday launch a drive to boost childhood vaccination rates, health authorities said, seeking an "urgent reversal" to a fall in uptake as the country faces a worsening measles outbreak. Routine childhood immunisations in Britain for diseases including measles, mumps and rubella, diphtheria and polio, have been falling gradually over the past decade, but dipped more sharply after the Covid-19 pandemic, mirroring a global decline. Last year UNICEF said people worldwide had lost confidence in the importance of routine childhood vaccines during the pandemic, with misinformation, dwindling trust in governments and political polarisation contributing to rising hesitancy. Britons will begin seeing adverts from next week across various media, including a television campaign featuring children reminding parents of the risk of missing out on vaccinations, the UK Health Security Agency (UKHSA) said. "We need an urgent reversal of the decline in the uptake of childhood vaccinations to protect our communities," UKHSA chief executive Jenny Harries said in a statement.

Thanks to increasing environmental awareness among people worldwide, there's a growing commitment to sustainable practices across industries. The healthcare sector, including pharmacies, is no exception. Recognising the fact that 'climate crisis is a health crisis', 124 countries signed a new Declaration on Climate and Health at the first-ever Health Day at the United Nations climate change conference, COP28 Dubai, which was held on 3 December 2023. The declaration acknowledged the need to prepare healthcare systems to cope with climate change and accelerate actions to protect communities. Welcoming the declaration, Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization (WHO) emphasized the need to build "climate-resilient and low-carbon" health systems to protect the health of both the planet and people. Pharmacies play a crucial role in providing essential medications and healthcare services to the community, but their operations can have environmental implications.